Premium
Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin
Author(s) -
Yee Ka Lai,
Cabalu Tamara D.,
Kuo Yuhsin,
Fillgrove Kerry L.,
Liu Yang,
Triantafyllou Ilias,
McClain Sasha,
Dreyer Daniel,
Wenning Larissa,
Stoch S. Aubrey,
Iwamoto Marian,
Sanchez Rosa I.,
Khalilieh Sauzanne G.
Publication year - 2021
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.1747
Subject(s) - rifabutin , cyp3a , pharmacology , pharmacokinetics , metabolite , reverse transcriptase inhibitor , rifamycin , drug interaction , chemistry , cyp3a4 , cytochrome p450 , medicine , antibiotics , metabolism , biochemistry , gene , reverse transcriptase , rna , clarithromycin
Abstract Doravirine, a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus 1 (HIV‐1), is predominantly cleared by cytochrome P450 (CYP) 3A4 and metabolized to an oxidative metabolite (M9). Coadministration with rifabutin, a moderate CYP3A4 inducer, decreased doravirine exposure. Based on nonparametric superposition modeling, a doravirine dose adjustment from 100 mg once daily to 100 mg twice daily during rifabutin coadministration was proposed. However, M9 exposure may also be impacted by induction, in addition to the dose adjustment. As M9 concentrations have not been quantified in previous clinical studies, a physiologically based pharmacokinetic model was developed to investigate the change in M9 exposure when doravirine is coadministered with CYP3A inducers. Simulations demonstrated that although CYP3A induction increases doravirine clearance by up to 4.4‐fold, M9 exposure is increased by only 1.2‐fold relative to exposures for doravirine 100 mg once daily in the absence of CYP3A induction. Thus, a 2.4‐fold increase in M9 exposure relative to the clinical dose of doravirine is anticipated when doravirine 100 mg twice daily is coadministered with rifabutin. In a subsequent clinical trial, doravirine and M9 exposures, when doravirine 100 mg twice daily was coadministered with rifabutin, were found to be consistent with model predictions using rifampin and efavirenz as representative inducers. These findings support the dose adjustment to doravirine 100 mg twice daily when coadministered with rifabutin.